Dr Anna Rowe

Institute of Cancer and Genomic Sciences
Trial Management Team Leader

Contact details

Cancer Research UK Clinical Trials Unit
Institute of Cancer and Genomic Sciences
Office 15, 5th Floor, East ITM, Heritage Building
Mindelsohn Way
Birmingham B15 2TH

Dr Anna Rowe is the Inflammation – Advanced and Cellular Therapy (I-ACT) Trial Management Team Leader at the Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences at the University of Birmingham.


  • PhD in Physiology (2006)
  • MSc Toxicology (2000)
  • BSc Pharmacology (1999)


Anna Rowe graduated with a 2:1 BSc (Hons) in Pharmacology from Sunderland University in 1999 before moving to Birmingham University.  Anna graduated with an MSc in Toxicology in 2000, and completed her PhD in 2006.  Her PhD investigated the role of Platelet Activating Factor in Necrotising Enterocolitis in premature neonates.

Anna joined CRCTU as a Trial Co-ordinator within the Early Drug Development Team in 2009 and was promoted to the role of Senior Trial Coordinator in 2015 (Early Drug Development/ Diagnostics, Drugs, Devices and Biomarker teams).  She was appointed as a Trial Management Team Leader in 2018 for the Inflammation – Advanced and Cellular Therapy team.

Anna’s trial experience is predominantly within early phase trials in both oncology and non-oncology, which includes the use of cell therapy products and novel compounds.

Anna is responsible for a portfolio of trials covering a range of areas including oncology, auto-immune liver conditions, Rheumatoid Arthritis and Inflammatory Bowel Disease.



Contributing to the design, set-up and management of clinical trials within the trials portfolios of the Birmingham Biomedical Research Centre; Midlands and Wales Advanced Therapy Treatment Centre (@AttcMw on Twitter ); and the Arthritis Therapy Acceleration Program.


Arndtz, K., Corrigan, M., Anna Rowe, Amanda Kirkham, Barton, D., Rich Fox, Llewellyn, L., Athwal, A., Wilkhu, M., Yung-Yi Chen, Christopher Weston, Desai, A., David Adams and Gideon Hirschfield. Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol. 1 Jun 2017, In : BMJ open. 7, 6, e015081.